Tags

Type your tag names separated by a space and hit enter

The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
Mov Disord. 2019 02; 34(2):246-254.MD

Abstract

BACKGROUND

MicroRNAs are small noncoding RNAs involved in the post-transcriptional regulation of protein synthesis. Extracellular microRNAs are accessible in a stable form in biofluids.

OBJECTIVES

The aim was to identify individual microRNAs and/or subsets of microRNAs in CSF with biomarker potential and thus identify specific putative pathophysiological pathways.

METHODS

In a two-step exploratory study design of PD, MSA, PSP, and controls, we initially profiled CSF microRNAs in a pilot cohort (n = 40) by screening for 372 microRNAs. Subsequently, we attempted to validate findings in an independent study cohort in CSF (n = 118) and ethylenediaminetetraacetic acid plasma (n = 114). This study cohort encompassed 46 microRNAs, of which 26 were singled out from the pilot cohort, and an additional 20 microRNAs were added based on previous publications. The most accurate diagnostic microRNA classifiers were identified in a multivariable logistic regression model adjusted for age and sex.

RESULTS

A set of three microRNAs in CSF discriminated PD and MSA from controls with good diagnostic accuracy by receiver operating characteristics curve evaluation. The microRNAs were for PD versus controls: miR-7-5p, miR-331-5p, and miR-145-5p (area under the curve = 0.88) and MSA versus controls: miR-7-5p, miR-34c-3p, and miR-let-7b-5p (area under the curve = 0.87). The classifier that best distinguished MSA and PD consisted of two microRNAs: miR-9-3p and miR-106b-5p (area under the curve = 0.73). A single microRNA, miR-106b-5p, provided the best discrimination between PD and PSP (area under the curve = 0.85) in the CSF.

CONCLUSIONS

Levels of specific trios of CSF-microRNAs discriminate well between α-synucleinopathies (PD and MSA) and controls. The results need to be validated in larger, independent cohorts. © 2018 International Parkinson and Movement Disorder Society.

Authors+Show Affiliations

Department of Neurology, Bispebjerg University Hospital, Copenhagen, Denmark.Department of Neurology, Bispebjerg University Hospital, Copenhagen, Denmark.Department of Autoimmunology and Biomarkers, Statens Serum Institute, Copenhagen, Denmark. Department of Clinical Biochemistry, University of Southern Denmark, Odense, Denmark.Department of Autoimmunology and Biomarkers, Statens Serum Institute, Copenhagen, Denmark.Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.Department of Microbiology and Infection Control, Statens Serum Institute, Copenhagen, Denmark.Department of Neurology, Bispebjerg University Hospital, Copenhagen, Denmark. Department of Neurology, Zealand University Hospital, Roskilde, Denmark.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30557454

Citation

Starhof, Charlotte, et al. "The Biomarker Potential of Cell-free microRNA From Cerebrospinal Fluid in Parkinsonian Syndromes." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 34, no. 2, 2019, pp. 246-254.
Starhof C, Hejl AM, Heegaard NHH, et al. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Mov Disord. 2019;34(2):246-254.
Starhof, C., Hejl, A. M., Heegaard, N. H. H., Carlsen, A. L., Burton, M., Lilje, B., & Winge, K. (2019). The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Movement Disorders : Official Journal of the Movement Disorder Society, 34(2), 246-254. https://doi.org/10.1002/mds.27542
Starhof C, et al. The Biomarker Potential of Cell-free microRNA From Cerebrospinal Fluid in Parkinsonian Syndromes. Mov Disord. 2019;34(2):246-254. PubMed PMID: 30557454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. AU - Starhof,Charlotte, AU - Hejl,Anne-Mette, AU - Heegaard,Niels H H, AU - Carlsen,Anting L, AU - Burton,Mark, AU - Lilje,Berit, AU - Winge,Kristian, Y1 - 2018/12/17/ PY - 2018/06/04/received PY - 2018/08/27/revised PY - 2018/08/30/accepted PY - 2018/12/18/pubmed PY - 2020/1/3/medline PY - 2018/12/18/entrez KW - CSF KW - Parkinson's disease KW - biomarker KW - microRNA KW - multiple system atrophy SP - 246 EP - 254 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 34 IS - 2 N2 - BACKGROUND: MicroRNAs are small noncoding RNAs involved in the post-transcriptional regulation of protein synthesis. Extracellular microRNAs are accessible in a stable form in biofluids. OBJECTIVES: The aim was to identify individual microRNAs and/or subsets of microRNAs in CSF with biomarker potential and thus identify specific putative pathophysiological pathways. METHODS: In a two-step exploratory study design of PD, MSA, PSP, and controls, we initially profiled CSF microRNAs in a pilot cohort (n = 40) by screening for 372 microRNAs. Subsequently, we attempted to validate findings in an independent study cohort in CSF (n = 118) and ethylenediaminetetraacetic acid plasma (n = 114). This study cohort encompassed 46 microRNAs, of which 26 were singled out from the pilot cohort, and an additional 20 microRNAs were added based on previous publications. The most accurate diagnostic microRNA classifiers were identified in a multivariable logistic regression model adjusted for age and sex. RESULTS: A set of three microRNAs in CSF discriminated PD and MSA from controls with good diagnostic accuracy by receiver operating characteristics curve evaluation. The microRNAs were for PD versus controls: miR-7-5p, miR-331-5p, and miR-145-5p (area under the curve = 0.88) and MSA versus controls: miR-7-5p, miR-34c-3p, and miR-let-7b-5p (area under the curve = 0.87). The classifier that best distinguished MSA and PD consisted of two microRNAs: miR-9-3p and miR-106b-5p (area under the curve = 0.73). A single microRNA, miR-106b-5p, provided the best discrimination between PD and PSP (area under the curve = 0.85) in the CSF. CONCLUSIONS: Levels of specific trios of CSF-microRNAs discriminate well between α-synucleinopathies (PD and MSA) and controls. The results need to be validated in larger, independent cohorts. © 2018 International Parkinson and Movement Disorder Society. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/30557454/The_biomarker_potential_of_cell_free_microRNA_from_cerebrospinal_fluid_in_Parkinsonian_Syndromes_ DB - PRIME DP - Unbound Medicine ER -